{"id":472206,"date":"2021-04-06T16:22:31","date_gmt":"2021-04-06T20:22:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=472206"},"modified":"2021-04-06T16:22:31","modified_gmt":"2021-04-06T20:22:31","slug":"homology-medicines-announces-proposed-public-offering-of-common-stock","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/","title":{"rendered":"Homology Medicines Announces Proposed Public Offering of Common Stock"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BEDFORD, Mass., April  06, 2021  (GLOBE NEWSWIRE) &#8212; Homology Medicines,\u00a0Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subject to market and other conditions, $50.0 million of its common stock in an underwritten public offering. Homology expects to grant the underwriter a 30-day option to purchase up to an additional $7.5 million of its common stock. All of the shares in the proposed offering are to be sold by Homology.<\/p>\n<p>BTIG is the sole book-running manager for the offering.<\/p>\n<p>Homology intends to use the net proceeds from the offering, in addition to its existing cash resources, to: continue to advance its lead gene therapy candidate, HMI-102, for the treatment of phenylketonuria (PKU) in adults through the ongoing Phase 2 pheNIX clinical trial; advance HMI-203, its gene therapy candidate for the treatment of Hunter syndrome, and HMI-103, its first gene editing candidate, which is for the treatment of PKU in the pediatric population, through IND-enabling studies and into clinical trials; advance its other pipeline programs through preclinical development; further expand its intellectual property portfolio; potentially further expand its manufacturing capacity; and for working capital and general corporate and administrative expenses.<\/p>\n<p>A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) and has been declared effective. The securities will be offered only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC\u2019s website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained, when available, from BTIG, LLC, 65 East 55th Street, New York, NY, 10022, by email at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=loJw9Qjg5FKxC8h8rAHj7K6R-QyMwU0kwHnkB54J7kvGMW-a_tGf2WYUwphYR22CVr_CwhFDXtG1IRlvTR4Bt0jmHGmZKOxWUHO4fCJvyuCboHa1SOW7i2dpi345Cwdn\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">prospectusdelivery@btig.com<\/a> or by telephone at (212) 593-7555.<\/p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n<p>\n        <strong>About Homology Medicines, Inc. <\/strong><br \/>\n        <br \/>Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology\u2019s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines <em>in vivo<\/em> either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the completion and anticipated use of proceeds of the proposed offering. All such forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to fluctuations in Homology\u2019s stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering, as well as the other factors discussed in the \u201cRisk Factors\u201d section in the registration statement referenced above and in Homology\u2019s most recently filed Annual Report on Form 10-K, as well as other risks detailed in Homology\u2019s filings with the Securities and Exchange Commission. There can be no assurance that Homology will be able to complete the proposed public offering on the anticipated terms. All information in this press release is as of the date of the release, and Homology undertakes no duty to update this information, even if subsequent events cause its views to change, unless required by law.<\/p>\n<p>\n        <strong>Company Contact<\/strong><br \/>\n        <br \/>Theresa McNeely<br \/>Chief Communications Officer <br \/>and Patient Advocate<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kkhbtH70WzjgPPqUzczxA29GHRCD3tFJNtd_iiY1B8_P-TTpkcTdwHAQRtZ7U_ATIdlJ-RivYFs6t1VXJK5DkpDCAN4jPDMfukIdr77OEbW39lbOdsLB35bNlnvctZxj\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">tmcneely@homologymedicines.com<\/a><br \/>781-301-7277<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjQ3MSM0MTA4NDA1IzIwOTc5NDM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e34c69a8-d92c-4154-a345-c8e08bb86d2f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) &#8212; Homology Medicines,\u00a0Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subject to market and other conditions, $50.0 million of its common stock in an underwritten public offering. Homology expects to grant the underwriter a 30-day option to purchase up to an additional $7.5 million of its common stock. All of the shares in the proposed offering are to be sold by Homology. BTIG is the sole book-running manager for the offering. Homology intends to use the net proceeds from the offering, in addition to its existing cash resources, to: continue to advance its lead gene therapy candidate, HMI-102, for the treatment of phenylketonuria &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Homology Medicines Announces Proposed Public Offering of Common Stock&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-472206","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Homology Medicines Announces Proposed Public Offering of Common Stock - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Homology Medicines Announces Proposed Public Offering of Common Stock - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) &#8212; Homology Medicines,\u00a0Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subject to market and other conditions, $50.0 million of its common stock in an underwritten public offering. Homology expects to grant the underwriter a 30-day option to purchase up to an additional $7.5 million of its common stock. All of the shares in the proposed offering are to be sold by Homology. BTIG is the sole book-running manager for the offering. Homology intends to use the net proceeds from the offering, in addition to its existing cash resources, to: continue to advance its lead gene therapy candidate, HMI-102, for the treatment of phenylketonuria &hellip; Continue reading &quot;Homology Medicines Announces Proposed Public Offering of Common Stock&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-06T20:22:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjQ3MSM0MTA4NDA1IzIwOTc5NDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Homology Medicines Announces Proposed Public Offering of Common Stock\",\"datePublished\":\"2021-04-06T20:22:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/\"},\"wordCount\":683,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjQ3MSM0MTA4NDA1IzIwOTc5NDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/\",\"name\":\"Homology Medicines Announces Proposed Public Offering of Common Stock - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjQ3MSM0MTA4NDA1IzIwOTc5NDM=\",\"datePublished\":\"2021-04-06T20:22:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjQ3MSM0MTA4NDA1IzIwOTc5NDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjQ3MSM0MTA4NDA1IzIwOTc5NDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/homology-medicines-announces-proposed-public-offering-of-common-stock\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Homology Medicines Announces Proposed Public Offering of Common Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Homology Medicines Announces Proposed Public Offering of Common Stock - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/","og_locale":"en_US","og_type":"article","og_title":"Homology Medicines Announces Proposed Public Offering of Common Stock - Market Newsdesk","og_description":"BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) &#8212; Homology Medicines,\u00a0Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subject to market and other conditions, $50.0 million of its common stock in an underwritten public offering. Homology expects to grant the underwriter a 30-day option to purchase up to an additional $7.5 million of its common stock. All of the shares in the proposed offering are to be sold by Homology. BTIG is the sole book-running manager for the offering. Homology intends to use the net proceeds from the offering, in addition to its existing cash resources, to: continue to advance its lead gene therapy candidate, HMI-102, for the treatment of phenylketonuria &hellip; Continue reading \"Homology Medicines Announces Proposed Public Offering of Common Stock\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-06T20:22:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjQ3MSM0MTA4NDA1IzIwOTc5NDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Homology Medicines Announces Proposed Public Offering of Common Stock","datePublished":"2021-04-06T20:22:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/"},"wordCount":683,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjQ3MSM0MTA4NDA1IzIwOTc5NDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/","name":"Homology Medicines Announces Proposed Public Offering of Common Stock - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjQ3MSM0MTA4NDA1IzIwOTc5NDM=","datePublished":"2021-04-06T20:22:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjQ3MSM0MTA4NDA1IzIwOTc5NDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjQ3MSM0MTA4NDA1IzIwOTc5NDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/homology-medicines-announces-proposed-public-offering-of-common-stock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Homology Medicines Announces Proposed Public Offering of Common Stock"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/472206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=472206"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/472206\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=472206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=472206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=472206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}